Belupo

Belupo, founded in 1971, stands as a prominent Croatian pharmaceutical and cosmetics company with a significant operational footprint across 18 European countries. The company is dedicated to solidifying its strong market position in Rx and OTC segments. Belupo actively pursues the development and launch of new products, with a strategic emphasis on expanding its presence in the OTC market, aiming for both regional and global growth. This focus underscores its commitment to innovation and market penetration within the healthcare sector.

Manufacturing drugs since 1971, Belupo has consistently invested in enhancing its production capabilities. This includes substantial greenfield investments, culminating in the completion of new solid and semi-solid manufacturing plants in 2017. The company employs between 500 - 1,000 professionals dedicated to driving its operations and strategic initiatives. Belupo's mid-term objectives involve further expansion into Central and Eastern European (CEE) and Southeastern European (SEE) markets, with a particular focus on CIS countries. This ambitious growth is supported by a team committed to achieving these objectives, and you can Meet Belupo's team to understand the expertise behind their expansion efforts.

Belupo's vision is to establish itself as a leading pharmaceutical company in Central and Eastern Europe. To achieve this, the company is concentrating on several new therapeutic groups and actively diversifying its existing product portfolio. This diversification and product development aims to enhance its competitive edge. Generating $146.8M in revenue, Belupo reflects substantial market presence and operational success. Belupo continues to leverage its manufacturing expertise and market insights to drive future growth and innovationView more...